Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Quantumscape Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while Quantumscape Corp trades at $3.87 (market cap $2.43B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 3.5× Quantumscape Corp's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| HNGE | QS | |
|---|---|---|
Market Cap | $8.47B | $2.43B |
Volume | 1,624,526 | 14,407,354 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $18.44 |
52-Week Low | $31.17 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $8.09B | $1.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
QuantumScape (QS) trades at $4.12, down 3.51% with a bearish technical outlook despite oversold RSI readings. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative ROE/ROA. Recent news highlights commercialization delays and insider selling, while analyst consensus shows 73% hold ratings with a $10.35 price target representing 151% upside potential.
QS presents high-risk speculation with substantial upside if solid-state battery technology succeeds, but faces execution risks and cash burn. The stock trades near 52-week lows with negative cash flow trends, requiring careful risk management given the 5+ year commercialization timeline and competitive threats in EV battery development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
